Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Patient characteristics

From: Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer

Characteristics

Median age in years (range)

71 (57–83)

Median KPS in % (range)

100 (70–100)

Median iPSA in ng/mL (range)

7.9 (3.3–25.4)

Median DIL volume in cm3 (range)

1.4 (0.4–6.6)

Gleason score

 6

5 (21.7%)

 7

13 (56.5%)

 8–10

5 (21.7%)

TNM stage

 cT1a-c

21 (91.3%)

 cT2a-c

2 (8.7%)

D’Amico risk group

 Low-risk

5 (21.7%)

 Intermediate-risk

11 (47.8%)

 High-risk

7 (30.4%)

Index lesion sector distribution

 Anterior fibromuscular stroma

8/23 (34.8%)

 Anterior TZ

6/23 (26.1%)

 Posterior TZ

5/23 (21.7%%)

 Anterior PZ

2/23 (8.7%)

 Posterior medial PZ

8/23 (34.8%)

 Posterior lateral PZ

11/23 (47.8%)

 Central zone

0/23 (0.0%)

  1. KPS Karnofsky Performance Status, iPSA initial prostate-specific antigen, DIL dominant intraprostatic lesion, TZ transition zone, PZ peripheral zone
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us